Cibus, Inc. (CBUS) Stock Price & Analysis
Cibus, Inc. (CBUS) fell 4.49% to USD 1.7 as of July 26, 2026 at 11:04 UTC, according to Nexqual real-time market data.
CBUS last closed at USD 1.78; the session ranged USD 1.68–1.81 on volume of 94,655 shares. Market capitalization is $137.66M, with a 52-week range of USD 1.09–4.19 (NCM). Source: Nexqual, July 26, 2026 at 11:04 UTC.
Key Statistics (as of July 26, 2026 at 11:04 UTC)
| Price | USD 1.7 |
|---|---|
| Change | ▼ 4.49% (down) |
| Previous Close | USD 1.78 |
| Open | USD 1.8 |
| Day Range | USD 1.68 – 1.81 |
| 52-Week Range | USD 1.09 – 4.19 |
| Volume | 94,655 shares |
| Market Cap | $137.66M |
| Exchange | NCM |
Technical Analysis (CBUS)
Nexqual's technical model rates CBUS "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 26, 2026 at 11:04 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.03 (neutral) |
| vs SMA50 | Above (USD 1.5) |
| MACD | 0.1 (positive) |
Analyst Ratings (CBUS)
Wall Street analysts rate CBUS "None" based on 3 analysts, with a mean price target of USD 14.67 (range USD 3–25), per Nexqual as of July 26, 2026 at 11:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 14.67 |
| High Target | USD 25 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (CBUS)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $1.75M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.12 ▼ miss |
| 2025-12-31 | USD -0.42 vs est -0.15 ▼ miss |
| 2025-09-30 | USD -0.44 vs est -0.18 ▼ miss |
| 2025-06-30 | USD -0.61 vs est -0.33 ▼ miss |
Source: Nexqual, July 26, 2026 at 11:04 UTC.
Financials & Fundamentals (CBUS)
| Total Revenue | $4.29M |
|---|---|
| Revenue Growth (YoY) | +62.60% |
| Gross Margin | +100.00% |
| Operating Margin | -721.00% |
| Profit Margin | +0.00% |
| ROE | -190.12% |
| Debt / Equity | 778.33 |
| Current Ratio | 2.37 |
| Total Cash | $30.32M |
| Total Debt | $276.15M |
| Free Cash Flow | $-52.74M |
Source: Nexqual, July 26, 2026 at 11:04 UTC.
Financial Health Score (CBUS)
Nexqual rates Cibus, Inc.'s overall financial health "Critical" across five dimensions, as of July 26, 2026 at 11:04 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $30M cash vs $276M debt |
| Cash Flow | Weak — FCF negative: -$53M, burning cash |
| Efficiency | Critical — ROE -190%, ROA -11.2% |
Ownership (CBUS)
| Insider Ownership | +26.13% |
|---|---|
| Institutional Ownership | +33.67% |
| Shares Outstanding | 76.33M |
| Float | 57.18M |
| Short % of Float | +6.18% |
Source: Nexqual, July 26, 2026 at 11:04 UTC.
Leadership (CBUS)
Cibus, Inc. is led by Craig Wichner (age 55), Chief Executive Officer, per Nexqual as of July 26, 2026 at 11:04 UTC.
| Chief Executive Officer | Craig Wichner (age 55) |
|---|---|
| Co-Founder, President & COO | Peter R. Beetham B.Sc. (age 62) |
| Co-Founder, Chief Scientific Officer & Executive VP | Gregory F. Gocal (age 56) |
| Co-Founder & Director | Rory Balfour Riggs (age 72) |
| Chief Financial Officer | Cornelis Broos M.Sc. (age 53) |
Major Backers & Investors (CBUS)
Notable institutional backers of Cibus, Inc. include FMR, LLC, Fidelity, Davidson Kempner Capital Management LP, according to Nexqual as of July 26, 2026 at 11:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.97% |
| Fidelity | 8.29% |
| Davidson Kempner Capital Management LP | 2% |
| Vantage Consulting Group, Inc | 1.5% |
| Weiss Asset Management Lp | 1.16% |
| United Capital Financial Advisors, LLC | 0.75% |
| Millennium Management | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.48% |
| BlackRock | 0.7% |
| Geode Capital | 0.63% |
Source: Nexqual, July 26, 2026 at 11:04 UTC.
From Cibus, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
- The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc. | USD 3.74 | ▲ 3.03% |
| ACRV | Acrivon Therapeutics, Inc. | USD 1.6 | ▼ 4.76% |
| GNLX | Genelux Corporation | USD 2.89 | ▼ 2.36% |
| COYA | Coya Therapeutics, Inc. | USD 4.25 | ▼ 2.75% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:04 UTC. This page is informational and not investment advice.